Kidney function and multiple hemostatic markers: cross sectional associations in the multi-ethnic study of atherosclerosis

被引:63
作者
Dubin, Ruth [1 ]
Cushman, Mary [2 ]
Folsom, Aaron R. [3 ]
Fried, Linda F. [4 ]
Palmas, Walter [5 ]
Peralta, Carmen A. [1 ,7 ]
Wassel, Christina [6 ]
Shlipak, Michael G. [1 ,7 ]
机构
[1] Univ Calif San Francisco, Div Nephrol, Dept Med, San Francisco, CA 94143 USA
[2] Fletcher Allen Hlth Care, Thrombosis & Hemostasis Program, Hematol Oncol Clin, Burlington, VT 05401 USA
[3] Div Epidemiol & Community Hlth, Minneapolis, MN 55454 USA
[4] 7E121 VA Pittsburgh Healthcare Syst, Div Nephrol, Univ Dr Ctr, Pittsburgh, PA 15240 USA
[5] Columbia Univ, Presbyterian Hosp, Dept Internal Med, New York, NY 10032 USA
[6] UCSD Sch Med, Dept Family & Prevent Med, La Jolla, CA 92093 USA
[7] San Francisco VA Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA
关键词
FACTOR PATHWAY INHIBITOR; CORONARY-ARTERY-DISEASE; VON-WILLEBRAND-FACTOR; CYSTATIN-C; CARDIOVASCULAR-DISEASE; TISSUE FACTOR; INFLAMMATORY BIOMARKERS; SOLUBLE THROMBOMODULIN; ELDERLY PERSONS; HEART-DISEASE;
D O I
10.1186/1471-2369-12-3
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background: Defined as estimated glomerular filtration rate (eGFR) < 60 ml/min/1.73 m2, chronic kidney disease (CKD) is strongly and independently associated with cardiovascular and overall mortality. We hypothesized that reduced kidney function would be characterized by abnormalities of hemostasis. Methods: We tested cross-sectional associations between (eGFR) and multiple hemostatic markers among 6751 participants representing a broad spectrum of kidney function in the Multi-Ethnic Study of Atherosclerosis (MESA). Kidney function was measured using cystatin C (eGFRcys) or creatinine, using CKD Epidemiology Collaboration (eGFRcr). Hemostatic markers included soluble thrombomodulin (sTM), soluble tissue factor (sTF), D-Dimer, von Willebrand factor (vWF), factor VIII, plasmin-antiplasmin complex (PAP), tissue factor pathway inhibitor (TFPI), plasminogen activator inhibitor-1 (PAI-1), and fibrinogen. Associations were tested using multivariable linear regression with adjustment for demographics and comorbidities. Results: In comparison to persons with eGFRcys >90 ml/min/1.73 m(2), subjects with eGFRcys < 60 ml/min/1.73 m(2) had adjusted levels of sTM, sTF, D-Dimer, PAP, Factor VIII, TFPI, vWF and fibrinogen that were respectively 86%, 68%, 44%, 22%, 17%, 15%, 12% and 6% higher. Subjects with eGFRcys 60-90 ml/min/1.73 m(2) had adjusted levels that were respectively 16%, 14%, 12%, 6%, 6%, 6%, 11% and 4% higher (p < 0.05 for all). Percent differences were not significantly different when groups were categorized by eGFRcr. Conclusions: Throughout a broad spectrum of kidney function, lower eGFR was associated with higher levels of hemostatic markers. Dysregulation of hemostasis may be a mechanism by which reduced kidney function promotes higher cardiovascular risk.
引用
收藏
页数:8
相关论文
共 44 条
[1]   Hypercoagulability in chronic kidney disease is associated with coagulation activation but not endothelial function [J].
Adams, M. J. ;
Irish, A. B. ;
Watts, G. F. ;
Ostryck, R. ;
Dogra, G. K. .
THROMBOSIS RESEARCH, 2008, 123 (02) :374-380
[2]  
[Anonymous], 2002, KDOQI DEFINITION CLA
[3]   Inflammation, Hemostasis, and the Risk of Kidney Function Decline in the Atherosclerosis Risk in Communities (ARIC) Study [J].
Bash, Lori D. ;
Erlinger, Thomas P. ;
Coresh, Josef ;
Marsh-Manzi, Jane ;
Folsom, Aaron R. ;
Astor, Brad C. .
AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 53 (04) :596-605
[4]   Multi-ethnic study of atherosclerosis: Objectives and design [J].
Bild, DE ;
Bluemke, DA ;
Burke, GL ;
Detrano, R ;
Roux, AVD ;
Folsom, AR ;
Greenland, P ;
Jacobs, DR ;
Kronmal, R ;
Liu, K ;
Nelson, JC ;
O'Leary, D ;
Saad, MF ;
Shea, S ;
Szklo, M ;
Tracy, RP .
AMERICAN JOURNAL OF EPIDEMIOLOGY, 2002, 156 (09) :871-881
[5]   Tissue Factor and Cardiovascular Disease: Quo Vadis? [J].
Breitenstein, Alexander ;
Tanner, Felix C. ;
Luescher, Thomas F. .
CIRCULATION JOURNAL, 2010, 74 (01) :3-12
[6]   Atherosclerotic cardiovascular disease risks in chronic hemodialysis patients [J].
Cheung, AK ;
Sarnak, MJ ;
Yan, GF ;
Dwyer, JT ;
Heyka, RJ ;
Rocco, MV ;
Teehan, BP ;
Levey, AS .
KIDNEY INTERNATIONAL, 2000, 58 (01) :353-362
[7]   Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure [J].
Chobanian, AV ;
Bakris, GL ;
Black, HR ;
Cushman, WC ;
Green, LA ;
Izzo, JL ;
Jones, DW ;
Materson, BJ ;
Oparil, S ;
Wright, JT ;
Roccella, EJ .
HYPERTENSION, 2003, 42 (06) :1206-1252
[8]   Evidence for increased cardiovascular disease risk in patients with chronic kidney disease [J].
Coresh, J ;
Astor, B ;
Sarnak, MJ .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2004, 13 (01) :73-81
[9]   Fibrinolytic activation markers predict myocardial infarction in the elderly - The cardiovascular health study [J].
Cushman, M ;
Lemaitre, RN ;
Kuller, LH ;
Psaty, BM ;
Macy, EM ;
Sharrett, AR ;
Tracy, RP .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 1999, 19 (03) :493-498
[10]   C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease [J].
Danesh, J ;
Wheeler, JG ;
Hirschfield, GM ;
Eda, S ;
Eiriksdottir, G ;
Rumley, A ;
Lowe, GDO ;
Pepys, MB ;
Gudnason, V .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (14) :1387-1397